Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel

We have previously established the efficacy of adenoviral gene delivery vectors for the treatment of bladder carcinoma in vivo. In the present work, we developed a gene therapy strategy for bladder cancer based on the replacement of the tumor suppressor p16, which is known to be mutated or deleted i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 1997-12, Vol.3 (12), p.2415-2423
Hauptverfasser:	GRIM, J, D'AMICO, A, FRIZELLE, S, ZHOU, J, KRATZKE, R. A, CURIEL, D. T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae Antineoplastic agents Biological and medical sciences Carcinoma, Non-Small-Cell Lung Cell Cycle - physiology Cell Survival - drug effects Cisplatin - toxicity Cyclin-Dependent Kinase Inhibitor p16 - biosynthesis Cyclin-Dependent Kinase Inhibitor p16 - deficiency Drug Resistance, Neoplasm G1 Phase General aspects Genes, p16 Genes, Retinoblastoma Genetic Therapy - methods Genetic Vectors Humans Lung Neoplasms Medical sciences Mesothelioma Paclitaxel - toxicity Pharmacology. Drug treatments Recombinant Proteins - biosynthesis Retinoblastoma Protein - biosynthesis Transfection - methods Tumor Cells, Cultured Urinary Bladder Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!